News

PS-Fertility, maker of a male fertility test, to establish HQ outside Charlottesville

Life sciences startup PS-Fertility Inc. will invest $1.4 million to build out a headquarters and laboratory in Albemarle County, the office of Virginia Gov. Glenn Youngkin announced Wednesday.

PS-Fertility is aiming to commercialize a male fertility diagnostic that was originally developed at the University of Virginia. The company will lease 4,000 square feet at 3030 Vision Lane, just south of Charlottesville’s city limits, for its headquarters and lab as well as a test kit assembly operation, according to the announcement. PS-Fertility said it plans to create 31 new jobs with the project.

The company’s diagnostic tests for the presence of a biomarker on sperm cells necessary for fertilization, which can offer information on male fertility. PS-Fertility plans to use an at-home collection model, where samples are mailed to the new lab from across the country.

CEO Kevin Combs said in a statement his company planned to launch “in the very near future.”

The Virginia Economic Development Partnership said it worked with Albemarle County to secure the project for the state. Its Virginia Jobs Investment Program will support PS-Fertility’s hiring efforts by providing consultative services and funding to support recruitment and training.

“Virginia is the birthplace of innovations, and PS-Fertility’s groundbreaking discovery demonstrates the importance of our entrepreneurial ecosystems that lead to new technologies and products, ultimately resulting in new jobs,” Caren Merrick, Virginia’s secretary of commerce and trade, said in a statement.

Read more here.

Recent News

01/27/2025

Haleon Expands Richmond Research and Development Facility

Governor Glenn Youngkin announced today that Haleon, a leading global consumer health company, will invest $54.2 million to upgrade its research & development facility in the City of Richmond. The modernization will enable the company to accommodate innovative technologies and expand its research capabilities. Governor Youngkin met with Haleon leadership in London in July 2024

01/23/2025

IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases

IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease (SCD) and other chronic conditions. The partnership will leverage IMMvention’s investigational small-molecule BACH1 inhibitors. BACH1 is thought to be a key

01/22/2025

Virginia Companies Expand into Global Markets through Commonwealth’s Trade Accelerator Program

Governor Glenn Youngkin today announced that 10 companies across the Commonwealth of Virginia are graduating from the Virginia Economic Development Partnership’s Virginia Leaders in Export Trade (VALET) program, and 17 companies have joined the two-year program. VALET, which now has 412 graduated companies, assists Virginia exporters that have firmly established domestic operations and are committed